Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy

Annals of Hematology

Volumn 93, Issue 11, 2014, Pages 1903-1911

  Salah Eldin, Manal A ^a   Ebrahim, Mohamed A ^a   El Sadda, Wael ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Diffuse large B cell lymphoma; Hepatic toxicity; Immunochemotherapy; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; CLINICAL TRIAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84921811551     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2138-5     Document Type: Article

References (29)

1. El Hoofnagle J, Tralka TS (1997) Introduction: The National Institutes of Health Consensus Development Conference: management of hepatitis C virus. Hepatology 26(3):1S–2S, supplement
2. Zignego AL, Macchia D, Monti M, Thiers V, Mazzetti M, Foschi M, Maggi E, Romagnani S, Gentilini P, Bréchot C (1992) Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 15(3):382–386
3. Zignego AL, Giannini C, Monti M, Gragnani L (2007) Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 39(1):S38–S45
4. Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti M, Longombardo G, Lombardini F, Greco F, Capochiani E, Mazzoni A et al (1994) Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol 88(2):392–394
5. Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L, Russo D, Falasca E, Botta GA, Baccarani M (1996) Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 87(10):4296–4301
6. Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M et al (1997) Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 127(6):423–428
7. Dal Maso L, Franceschi S (2006) Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 15:2078–2085
8. Rai R, Weiss LM (2000) Hepatitis V virus and non-Hodgkin’s lymphoma. Am J Clin Pathol 109:508–509
9. TIN-HsLPF P (1993) a predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994
10. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242
11. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379–391
12. Ziakas PD, Karsaliakos P, Mylonakis E (2009) Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 94:998–1005
13. Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM et al (1998) Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 83:1224–1230
14. Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, Bonoldi E et al (2006) Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 17(9):1434–1440
15. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A et al (2006) Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte programs. J Clin Oncol 24(6):953–960
16. El-Zanaty F, Way A (2009) Egypt Demographic and Health Survey 2008. Egyptian: Ministry of Health. Cairo: El-Zanaty and Associates, and Macro International
17. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835–3849
18. Dizdar O, Tapan U, Aksoy S, Harputluoglu H, Saadettin Kilickap S, Barista I et al (2008) Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. Eur J Haematol 80:381–385
19. Merli M, Visco C, Spina M, Luminari S, Ferretti V, Gotti M, Rattotti S, Fiaccadori V, Rusconi C, Targhetta C, Stelitano C, Levis A, Ambrosetti A, Rossi D, Rigacci L, D’Arco A, Musto P, Chiappella A, Baldini L, Bonfichi M, Arcaini L (2014) Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 99(3):489–496
20. Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J et al (2010) Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 116(24):5119–5125
21. Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T, Hara T et al (2005) Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 74:158–165
22. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827–3834
23. Lake-Bakaar G, Dustin L, McKeating J, Newton K, Freeman V, Frost SD (2007) Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 109:845–846
24. Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, Rattotti S, Orlandi E, Rumi E, Ferretti V, Rizzi S, Meli E, Pascutto C, Paulli M, Lazzarino M (2010) Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol 85:46–50
25. Marignani M, Mangone M, Cox MC, Angeletti S, Veggia B, Ferrari A, di Fonzo M, Begini P, Gigante E, Laverde G, Aloe- Spiriti A, Monarca B, Delle Fave G (2011) HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis 43:139–142
26. Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Okamoto H, Tanimoto M, Hatake K (2008) Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 83:59–62
27. Nishikawa H, Tsudo M, Osaki Y (2012) Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. Oncol Rep 28:835–840
28. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027–5033
29. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127